| Name | Title | Contact Details |
|---|---|---|
Jay Gelfman |
Vice President Finance | Profile |
Syntimmune approaches areas of high unmet medical need in a unique way. Instead of searching for novel, unproven disease biology, Syntimmune focuses on areas of science that are well understood and extensively researched. We seek new treatments that build on these areas of scientific consensus and broad applicability. In the case of our lead drug candidate, SYNT001, both the cellular pathway and the specific molecular target have been studied extensively for more than 25 years, spearheaded by the groundbreaking research of the scientific team behind Syntimmune. Building on proven areas of science enables Syntimmune to advance its drug candidates swiftly and predictably. The result is a significantly derisked approach to new drug development. More importantly, we believe our approach speeds approval of medicines for patients in areas where existing treatments involve inconvenience, dangerous side effects, or poor efficacy. In an industry that often places a premium on novelty, Syntimmune understands that creating real value comes from helping patients who are suffering with diseases for which current treatments are inadequate or nonexistent.
J. Craig Venter Institute (JVCI) is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Amira Pharmaceuticals is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Genome British Columbia is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
deCODE genetics is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.